clazosentan 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| endothelin receptor antagonists | 5518 | 180384-56-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Clazosentan is an endothelin receptor antagonist indicated for the prevention of cerebrovascular spasm after surgery for subarachnoid hemorrhage caused by cerebral aneurysm, and cerebral infarctions and cerebral ischemic symptoms accompanying the cerebrovascular spasm.
|
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 20, 2022 | PMDA | IDORSIA PHARMACEUTICALS JAPAN LTD |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
None
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Prevention of cerebrovascular spasm | indication | 73173006 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Endothelin-1 receptor | GPCR | ANTAGONIST | Ki | 9.89 | CHEMBL | SCIENTIFIC LITERATURE | |||
| Endothelin B receptor | GPCR | Ki | 6.76 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| CHEMBL109648 | ChEMBL_ID |
| C109641 | MESH_SUPPLEMENTAL_RECORD_UI |
| 12286 | IUPHAR_LIGAND_ID |
| 503271-02-1 | SECONDARY_CAS_RN |
| DB06677 | DRUGBANK_ID |
| C1721268 | UMLSCUI |
| D11664 | KEGG_DRUG |
| 8397 | INN_ID |
| 6433095 | PUBCHEM_CID |
| 3DRR0X4728 | UNII |
Pharmaceutical products:
None